Skip to main content

Table 4 Statins and CRC

From: Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case–control study

    

Odds ratios (95% CI)

 

Controls (%)

CRC (%)

P-value

Unadjusted

Adjusted*

any previous use

68/132 (51.5)

20/101 (19.8)

< 0.01

0.23 (0.13 – 0.42)

0.43 (0.25 – 0.80)

Duration

     

< 2 years

14 (11%)

8 (8)

0.47

0.73 (0.56 – 3.43)

0.66 (0.21 – 1.69)

2 – 5 years

23 (17)

7 (7)

0.05

0.35 (0.15 – 0.86)

0.38 (0.14 – 1.01)

> 5 years

31 (24)

5 (5)

< 0.01

0.17 (0.063 – 0.454)

0.18 (0.06 – 0.55)

Dose

     

< 40 mg/day

28 (21)

12 (12)

0.14

0.50 (0.24 – 1.04)

0.51 (0.21 – 1.24)

= or>40 mg/day

40 (30)

8 (8)

< 0.01

0.20 (0.09 – 0.45)

0.19 (0.07 – 0.47)

statin type

     

simvastatin

49 (37)

14 (14)

< 0.01

0.27 (0.14 – 0.53)

0.43 (0.10 – 0.73)

other

19 (14)

6 (6)

0.09

0.38 (0.14 – 0.98)

0.49 (0.13 – 1.13)

  1. Use of statins in patients with colorectal cancer (CRC) and controls. Results expressed as odds ratio with 95% confidence intervals (95% CI). *Adjusted for age, gender, type II diabetes, aspirin use, metformin use and weekly alcohol intake and compared to never used statins.